Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism in patients undergoing total hip replacement surgery

被引：0
|
作者：
Bradley-Kennedy, C. [1 ]
Wolowacz, S. E. [2 ]
Roskell, N. S. [3 ]
Plumb, J. M. [4 ]
机构：
[1] Boehringer Ingelheim Ltd, Hlth Econ & Outcomes Res, Burlington, ON, Canada
[2] RTI Hlth Solut Ltd, Hlth Econ, Manchester, England
[3] RTI Hlth Solut Ltd, Biometr, Manchester, England
[4] Boehringer Ingelheim GmbH & Co KG, Hlth Econ & Outcomes Res, Ingelheim, Germany
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-WE-470
引用
收藏
页码：786 / 786
页数：1
相关论文
共 50 条
  • [41] Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands
    Stevanovic, J.
    de Jong, L. A.
    Kappelhoff, B. S.
    Dvortsin, E. P.
    Voorhaar, M.
    Postma, M. J.
    PLOS ONE, 2016, 11 (10):
  • [42] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS DABIGATRAN FOR THROMOBOPROPHYLAXIS IN TOTAL HIP REPLACEMENT SURGERY IN THE UNITED STATES
    Raval, A.
    Vyas, A.
    Kamal, K.
    VALUE IN HEALTH, 2014, 17 (03) : A116 - A116
  • [43] Dabigatran etexilate 150 mg once daily for the prevention of venous thromboembolism after total knee or hip replacement surgery in the elderly and those with moderate renal impairment
    Dahl, O. E.
    Kurth, A. A.
    Rosencher, N.
    Clemens, A.
    Feuring, M.
    Noack, H.
    Eriksson, B., I
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 695 - 696
  • [44] ORAL PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE OR HIP REPLACEMENT SURGERY IN THE ELDERLY AND THOSE WITH MODERATE RENAL IMPAIRMENT: EFFICACY AND SAFETY PROFILE OF DABIGATRAN ETEXILATE
    Dahl, O. E.
    Kurth, A. A.
    Rosencher, N.
    Clemens, A.
    Feuring, M.
    Noack, H.
    Eriksson, B. I.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 179 - 179
  • [45] Dabigatran EtexilateA Review of its Use for the Prevention of Venous Thromboembolism after Total Hip or Knee Replacement Surgery
    Celeste B. Burness
    Kate McKeage
    Drugs, 2012, 72 : 963 - 986
  • [46] Cost-effectiveness of prevention of venous thromboembolism
    Sharp, B.
    Davies, A. H.
    PHLEBOLOGY, 2006, 21 : 29 - 31
  • [47] Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery
    Sullivan, SD
    Kwong, L
    Nutescu, E
    VALUE IN HEALTH, 2006, 9 (02) : 68 - 76
  • [48] COST-EFFECTIVENESS OF APIXABAN AND ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT IN CHINA
    Yan, X. Y.
    Gu, X. H.
    Bu, J.
    Lin, H. W.
    Wu, B.
    VALUE IN HEALTH, 2016, 19 (07) : A651 - A651
  • [49] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL HIP AND KNEE REPLACEMENT (THR, TKR) IN CHINESE PATIENTS
    Chen, X. B.
    Eggington, S.
    Wang, C. Y.
    Zhu, M.
    VALUE IN HEALTH, 2010, 13 (07) : A520 - A520
  • [50] COST-EFFECTIVENESS ANALYSIS OF BEMIPARIN AS PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN TOTAL KNEE REPLACEMENT SURGERY IN MEXICO
    Carlos, F.
    Aguirre, A.
    Esquivel, R.
    Nettel, J.
    Meillon, L.
    Bierschwale, H.
    VALUE IN HEALTH, 2012, 15 (07) : A445 - A445
12345